{
    "nct_id": "NCT02990481",
    "official_title": "A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Patients with histologically confirmed locally advanced or metastatic solid carcinomas in Arm 1\n* Patients with histologically confirmed locally advanced or metastatic colon cancer in Arm 2\n* Patients with histologically confirmed locally advanced or metastatic cholangiocarcinomas in Arm 3\n* Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy or not amendable to a curative treatment\n* Measurable disease per RECIST 1.1 (primary or metastases)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy\n* Pregnant or nursing women\n* Treatment with radiation therapy, surgery, chemotherapy, immunotherapy, or investigational therapy within four weeks prior to study entry\n* Unwillingness or inability to comply with procedures required in this protocol\n* Known active infection with HIV, hepatitis B, hepatitis C\n* Symptomatic brain metastases\n* Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor\n* Patients who are currently receiving any other investigational agent",
    "miscellaneous_criteria": ""
}